News coverage about Relypsa (NASDAQ:RLYP) has been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Relypsa earned a news impact score of 0.22 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 44.3008394333466 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

TRADEMARK VIOLATION WARNING: This piece was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/11/relypsa-nasdaqrlyp-getting-somewhat-favorable-news-coverage-study-shows.html.

About Relypsa

Relypsa, Inc is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company’s technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address.

Receive News & Ratings for Relypsa Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc and related companies with MarketBeat.com's FREE daily email newsletter.